Biotech Values

[exwannabe]

Re: MNTA, TEVAs ANDA status

"What I also find bullish here is that Teva is stating in January that their full immunogenicity testing results were submitted no later than January of 2010. And yet you still have Teva speculating that since they submitted their data a month after MNTA, that perhaps the delay of obtaining approval is that the FDA has had one last month to review this data.

Come on, it is August for crying out loud!. It has been at least 8 months, and 9 months for MNTA. That seems to be about as fecetious of reasoning as any I can think of. "

I disagree strongly with you. The argument that it could take the FDA the same 9 months for TEVA that they took for MNTA is certainly somewhat rational.

More importantly, this argument will play very well with the average investor, who has absolutely 0 clue what the FDA was discussing in the reply to the CP.

The good side to this is that it sets a window for when a "soon" decision would be. Once a few months have gone by, TEVA is obviously having issue(s) with the FDA, and that will be obvious to the more casual investors.

So a significant amount of market assigned risk will lift in the next few months. I would expect that around the time of the next Q CC we should see a return to a more reasonable valuation (presuming no bad news or course).